⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20625136 | 1.00 | — | — | |
| SCHEMBL16577400 | 1.00 | — | — | |
| SCHEMBL20625284 | 1.00 | — | — | |
| SCHEMBL17014388 | 1.00 | — | — | |
| SCHEMBL18583903 | 1.00 | — | — | |
| SCHEMBL23706944 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11820775 | 0.97 | ACE (0.42) | — | |
| SCHEMBL17972853 | 0.85 | ANPEP (0.41) | — | |
| SCHEMBL1886149 | 0.83 | LMNA (0.48) | — | |
| SCHEMBL1886148 | 0.83 | LMNA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| US-20230250058-A1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | ACCURE THERAPEUTICS, S.L. (ES) | 2023-08-10 | — | — | US | disclosed |
| CN-111201226-B | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2022-07-22 | — | — | CN | disclosed |
| EP-3592740-B1 | CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | PFIZER (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3592740-B1 | CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | PFIZER (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2928885-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086894-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086894-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2014-06-12 | — | — | WO | disclosed |
| EP-2533644-A1 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011100384-A1 | DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-08-18 | — | — | WO | disclosed |